About
Immunotherapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalVirginia, DC, DE & Maryland
Clinical Trials (18)
View allTotal Trials
18
As Lead Sponsor
6
As Collaborator
12
Total Enrollment
821
By Phase
PHASE1: 9PHASE1/PHASE2: 4PHASE2: 4EARLY_PHASE1: 1
By Status
TERMINATED: 6RECRUITING: 4NOT_YET_RECRUITING: 2WITHDRAWN: 2ACTIVE_NOT_RECRUITING: 2COMPLETED: 2
Clinical Trials Pipeline18 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
Today
Hover over trial bars to see details
Recent Trials
NCT07200089Collaborator
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
PHASE1Not yet recruiting
40 participants
Started: Jan 31, 2026 · Completed: Jul 31, 2028
NCT07052305Collaborator
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta® (Axicabtagene Ciloleucel) or Post-Breyanzi® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma
PHASE1Not yet recruiting
24 participants
Started: Oct 31, 2025 · Completed: Apr 30, 2028
NCT05600920Collaborator
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
PHASE1/PHASE2Recruiting
60 participants
Started: Nov 6, 2024 · Completed: Nov 1, 2026
NCT04054752Collaborator
Vaccine Response With NT-I7
PHASE1Withdrawn
Started: May 30, 2023 · Completed: Nov 1, 2023
NCT05465954Collaborator
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
PHASE2Recruiting
54 participants
Started: Jan 24, 2023 · Completed: Oct 15, 2028
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...